JNJ-77474462
Sponsors
Janssen Research & Development, LLC
Conditions
Healthy
Phase 1
A Study of JNJ-77474462 (Bermekimab) in Healthy Participants of Japanese Descent Following Administration of Single Ascending Subcutaneous Doses
CompletedNCT04544826
Start: 2020-10-16End: 2021-08-05Updated: 2021-09-29
A Study of JNJ-77474462 in Healthy Participants
CompletedNCT04544813
Start: 2020-10-13End: 2021-05-30Updated: 2023-06-29
A Study of JNJ-77474462 (Bermekimab) in Healthy Chinese Participants
WithdrawnNCT05252520
Start: 2023-05-01End: 2023-11-20Updated: 2025-02-03